Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema

New England Journal of Medicine

Volumn 372, Issue 13, 2015, Pages 1193-1203

  Wells, John A ^a   Glassman, Adam R ^b   Ayala, Allison R ^b   Jampol, Lee M ^c   Aiello, Lloyd Paul ^d   Antoszyk, Andrew N ^e   Arnold Bush, Bambi ^b   Baker, Carl W ^f   Bressler, Neil M ^e   Browning, David J ^g   Elman, Michael J ^h   Ferris, Frederick L ⁱ   Friedman, Scott M ^j   Melia, Michele ^b   Pieramici, J ^k   Sun, Jennifer K ^d   Beck, Roy W ^b  

^a Palmetto Retina Center   (United States)

^b JAEB CENTER FOR HEALTH RESEARCH   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e Charlotte Eye Ear   (United States)

^f Paducah Retinal Center   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h Elman Retina Group   (United States)

ⁱ NATIONAL EYE INSTITUTE   (United States)

^j Florida Retina Consultants   (United States)

^k California Retina Consultants   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ADULT; ADVERSE DRUG REACTION; ALGORITHM; ARTICLE; CARDIOVASCULAR DISEASE; CATARACT; CEREBROVASCULAR ACCIDENT; CLINICAL PROTOCOL; CONTROLLED STUDY; DEATH; DIABETIC MACULAR EDEMA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; EYE INFLAMMATION; FEMALE; GASTROINTESTINAL DISEASE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; VISUAL ACUITY; VITREOUS HEMORRHAGE; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETIC RETINOPATHY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MIDDLE AGED; PATHOLOGY; RETINA; THERAPEUTIC EQUIVALENCE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETIC RETINOPATHY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINA; THERAPEUTIC EQUIVALENCY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84925423332     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1414264     Document Type: Article

References (35)

1. Varma R, Bressler NM, Doan QV, et al. Prevalence and risk factors for diabetic macular edema in the United States. JAMA Ophthalmol 2014;132:1334-40.
2. Shea AM, Curtis LH, Hammill BG, et al. Resource use and costs associated with diabetic macular edema in elderly persons. Arch Ophthalmol 2008;126:1748-54.
3. Diabetes: facts and figures. Brussels: International Diabetes Federation, 2014 (http://www.idf.org/worlddiabetesday/toolkit/gp/facts-figures).
4. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7.
5. Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem 1999;274:23463-7.
6. Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-77.
7. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012;119:789-801.
8. Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the Ranibizumab for Edema of the Macula in Diabetes (READ-2) study. Ophthalmology 2010;117:2146-51.
9. Diabetic Retinopathy Clinical Research Network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114:1860-7.
10. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118:615-25.
11. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 2010;117:1078-86.
12. Arevalo JF, Sanchez JG, Fromow-Guerra J, et al. Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up. Graefes Arch Clin Exp Ophthalmol 2009;247:735-43.
13. Do DV, Nguyen QD, Boyer D, et al. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 2012;119:1658-65.
14. American Society of Retina Specialists Preference and Trends (PAT) Survey 2013 (http://www.asrs.org/asrs-community/pat-survey).
15. Arevalo JF, Lasave AF, Wu L, et al. Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema: results of the Pan-American Collaborative Retina Study Group at 24 months. Retina 2013;33:403-13.
16. Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology 2014;121:2247-54.
17. Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013;120:2013-22.
18. Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 2012;130:972-9.
19. Beck RW, Moke PS, Turpin AH, et al. A computerized method of visual acuity testing: adaptation of the Early Treatment of Diabetic Retinopathy Study testing protocol. Am J Ophthalmol 2003;135:194-205.
20. Diabetic Retinopathy Clinical Research Network Writing Committee. Reproducibility of spectral-domain optical coherence tomography retinal thickness measurements and conversion to equivalent time-domain metrics in diabetic macular edema. JAMA Ophthalmol 2014;132:1113-22.
21. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800-2.
22. Schafer JL. Multiple imputation: a primer. Stat Methods Med Res 1999;8:3-15.
23. Spiegelman D, Hertzmark E. Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol 2005;162:199-200.
24. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
25. Aflibercept. Tarrytown, NY: Regeneron, 2012 (package insert) (https://www.regeneron.com/Eylea/eylea-fpi.pdf).
26. Bevacizumab. South San Francisco, CA: Genentech, 2004 (package insert) (http://www.gene.com/download/pdf/avastin-prescribing.pdf).
27. Lucentis. South San Francisco, CA: Genentech, 2014 (package insert) (http://www.gene.com/download/pdf/lucentis-prescribing.pdf).
28. Zou L, Lai H, Zhou Q, Xiao F. Lasting controversy on ranibizumab and bevacizumab. Theranostics 2011;1:395-402.
29. Bressler NM, Boyer DS, Williams DF, et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina 2012;32:1821-8.
30. Virgili G, Parravano M, Menchini F, Evans JR. Anti-vascular endothelial growth factor for diabetic macular oedema. Cochrane Database Syst Rev 2014;10:CD007419.
31. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
32. Committee for Medicinal Products for Human Use. Assessment report: Eylea. London: European Medicines Agency, 2012.
33. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-98.
34. Moja L, Lucenteforte E, Kwag KH, et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2014;9:CD011230.
35. Yannuzzi NA, Klufas MA, Quach L, et al. Evaluation of compounded bevacizumab prepared for intravitreal injection. JAMA Ophthalmol 2015;133:32-9.